Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis

Osteoarthritis and Cartilage

Volumn 18, Issue 10, 2010, Pages 1256-1262

  Guler Yuksel M ^a   Allaart, C F ^a   Watt, I ^a   Goekoop Ruiterman, Y P M ^a   de Vries Bouwstra, J K ^a   van Schaardenburg, D ^b,c   van Krugten, M V ^d   Dijkmans, B A C ^b,c   Huizinga, T W J ^a   Lems, W F ^b,c   Kloppenburg, M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JAN VAN BREEMEN INSTITUTE   (Netherlands)

^d Ziekenhuis Walcheren   (Netherlands)

Author keywords

Inflammation; Infliximab; Osteoarthritis; Rheumatoid arthritis; TNF inhibitor

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGE; ARTICLE; ATLAS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE INCREASE; EROSION; ERYTHROCYTE; FEMALE; HAND RADIOGRAPHY; HUMAN; INCIDENCE; INFLAMMATION; INTERPHALANGEAL JOINT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OSTEOARTHRITIS; OSTEOPHYTE; POPULATION; POSTMENOPAUSE; PRIORITY JOURNAL; PROXIMAL INTERPHALANGEAL JOINT; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SEDIMENTATION RATE; TUMOR NECROSIS; X RAY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; FEMALE; HAND JOINTS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; OSTEOARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956881606     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2010.07.011     Document Type: Article

References (34)

1. Samuels J., Krasnokutsky S., Abramson S.B. Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis 2008, 66:244-250.
2. Slatkowsky-Christensen B., Mowinckel P., Loge J.H., Kvien T.K. Health-related quality of life in women with symptomatic hand osteoarthritis: a comparison with rheumatoid arthritis patients, healthy controls, and normative data. Arthritis Rheum 2007, 57:1404-1409.
3. Rogers J., Shepstone L., Dieppe P. Is osteoarthritis a systemic disorder of bone?. Arthritis Rheum 2004, 50:452-457.
4. Spector T.D., Hart D.J., Nandra D., Doyle D.V., Mackillop N., Gallimore J.R., et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997, 40:723-727.
5. Sharif M., Shepstone L., Elson C.J., Dieppe P.A., Kirwan J.R. Increased serum C reactive protein may reflect events precede radiographic progression in osteoarthritis of the knee. Ann Rheum Dis 2000, 59:71-74.
6. Pearle A.D., Scanzello C.R., George S., Mandl L.A., DiCarlo E.F., Peterson M., et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage 2007, 15:516-523.
7. Bos S.D., Suchiman H.E., Kloppenburg M., Houwing-Duistermaat J.J., le Graverand M.P., Seymour A.B., et al. Allelic variation at the C-reactive protein gene associates to both hand osteoarthritis severity and serum high sensitive C-reactive protein levels in the GARP study. Ann Rheum Dis 2008, 67:877-879.
8. Tan A.L., Grainger A.J., Tanner S.F., Shelley D.M., Pease C., Emery P., et al. High-resolution magnetic resonance imaging for the assessment of hand osteoarthritis. Arthritis Rheum 2005, 52:2355-2365.
9. Grainger A.J., Farrant J.M., Connor P.J., Tan A.L., Tanner S., Emery P., et al. MR imaging of erosions in interphalangeal joint osteoarthritis: is all osteoarthritis erosive?. Skeletal Radiol 2007, 36:737-745.
10. Goldring M.B. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res 1999, 40:1-11.
11. Fernandes J.C., Martel-Pelletier J., Pelletier J.P. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002, 39:237-246.
12. Smith M.D., Triantafillou S., Parker A., Youssef P.P., Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997, 24:365-371.
13. Riyazi N., Slagboom E., de Craen A.J., Meulenbelt I., Houwing-Duistermaat J.J., Kroon H.M., et al. Association of the risk of osteoarthritis with high innate production of interleukin-1ß and low innate production of interleukin-10 ex vivo upon lipopolysaccharide stimulation. Arthritis Rheum 2005, 52:1443-1450.
14. Botha-Scheepers S., Watt I., Slagboom E., de Craen A.J., Meulenbelt I., Rosendaal F.R., et al. Innate production of tumour necrosis factor alpha and interleukin 10 is associated with radiological progression of knee osteoarthritis. Ann Rheum Dis 2008, 67:1165-1169.
15. Abramson S.B., Yazici Y. Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. Adv Drug Deliv Rev 2006, 58:212-225.
16. Pelletier J.P., Martel-Pelletier J., Abramson S.B. Osteoarthritis an inflammatory disease: potential implications for the selection of new therapeutic agents. Arthritis Rheum 2001, 44:1237-1247.
17. Goldring M.V. Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther 2001, 1:817-829.
18. Farahat M.N., Yanni G., Poston R., Panayi G.S. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1993, 52:870-875.
19. Haraoui B., Pelletier J.P., Cloutier J.M., Faure M.P., Martel-Pelletier J. Synovium membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of anti-rheumatic drugs. Arthritis Rheum 1991, 34:153-163.
20. Kammermann J.R., Kincaid S.A., Rumph P.F., Baird D.K., Visco D.M. Tumor necrosis factor-alpha (TNF-alpha) in canine osteoarthritis: immunolocalization of TNF-alpha, stromelysin and TNF receptors in canine osteoarthritic cartilage. Osteoarthritis Cartilage 1996, 4:23-34.
21. Venn G., Nietfeld J.J., Duits A.J., Brennan F.M., Arner E., Convington M., et al. Elevated synovial fluid levels of interleukin-6 and tumor necrosis factor associated with early experimental canine osteoarthritis. Arthritis Rheum 1993, 36:819-826.
22. Westacott C.I., Whicher J.T., Barnes I.C., Thompson D., Swan A.J., Dieppe P.A. Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis 1990, 49:676-681.
23. Miller V.E., Rogers K., Muirden K.D. Detection of tumor necrosis factor alpha and interleukin-1 in the rheumatoid osteoarthritic cartilage-pannus junction by immunohistochemical methods. Rheumatol Int 1993, 13:77-82.
24. Vuolteenaho K., Moilanen T., Hamalainen M., Moilanen E. Effects of TNF-α antagonists on nitric oxide production in human cartilage. Osteoarthritis Cartilage 2002, 10:327-332.
25. Magnano M.D., Chakravarty E.F., Broudy C., Chung L., Kelman A., Hillygus J., et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007, 34:1323-1327.
26. Fioravanti A., Fabbroni M., Cerase A., Galeazzi M. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int 2009, 29:961-965.
27. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens P.J., Hazes J.M., et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007, 146:406-415.
28. Altman R.D., Gold G.E. Atlas of individual radiographic features in osteoarthritis, revised. Osteoarthritis Cartilage 2007, 15:S1-56.
29. van der Heijde D. How to read radiographs according to the Sharp-van der Heijde method. J Rheumatol 1999, 26:731-739.
30. Zhang M.B., Yu K.F. What's the relative risk?. JAMA 1998, 280:1690-1691.
31. Grunke M., Schulze-Koops H. Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockkade. Ann Rheum Dis 2006, 65:555-556.
32. van der Kraan P.M., van den Berg W.B. Osteophytes: relevance and biology. Osteoarthritis Cartilage 2007, 15:237-244.
33. Karsdal M.A., Leeming D.J., Dam E.B., Henriksen K., Alexandersen P., Pastoureau P., et al. Should subchondral bone turnover be targeted when treating osteoarthritis?. Osteoarthritis Cartilage 2008, 16:638-646.
34. Hayami T., Pickarski M., Wesolowski G.A., McLane J., Bone A., Destefano J., et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transaction model. Arthritis Rheum 2004, 50:1193-1206.